# A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

> **NCT04701658** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 109 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Bamlanivimab

## Key facts

- **NCT ID:** NCT04701658
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2021-06-22
- **Final completion:** 2021-06-22
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2021-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04701658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04701658, "A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04701658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*